Melden Sie sich bitte kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Melden Sie sich bitte kostenlos und unverbindlich an, um den Inhalt vollständig einzusehen und weitere Services von www.medmedia.at zu nutzen.

Alopecia areata
Baricitinib, Olumiant®, JAK1/2, Ritlecitinib, Litfulo®, JAK3/TEC, Upadacitinib, Rinvoq®, JAK1
Atopische Dermatitis
Abrocitinib, Cibinqo®, JAK1, Baricitinib, Olumiant®, JAK1/2, Dupilumab, Dupixent®, IL-4/IL-13, Lebrikizumab, Ebglyss®, IL-13, Nemolizumab, Nemluvio®, IL-31RA, Ruxolitinib, Opzelura®, Tralokinumab, Adtralza®, Upadacitinib, Rinvoq®
Chronisch spontane Urtikaria
Dupilumab, Dupixent®, IL-4/IL-13, Omalizumab, Xolair®; Biosimilar: Omlyclo®, IgE, Remibrutinib, Rhapsido®, BTK
Chronisches Handekzem
Delgocitinib, Anzupgo 20 mg/g Creme, JAK1/2/3, TYK2
Generalisierte pustulöse Psoriasis
Spesolimab, Spevigo®, IL-36R
Hidradenitis suppurativa
Adalimumab, Humira®; Biosimilars: Amgevita®, Amsparity®, Hefiya®, Hukyndra®, Hulio®, Hyrimoz®, Idacio®, Imraldi®, Libmyris®, Yuflyma®, TNF-α, Bimekizumab, Bimzelx®, IL-17A/IL-17F/IL-17AF, Secukinumab, Cosentyx®, IL-17A
Plaque-Psoriasis
Adalimumab, Humira®; Biosimilars: Amgevita®, Amsparity®, Hefiya®, Hukyndra®, Hulio®, Hyrimoz®, Idacio®, Imraldi®, Libmyris®, Yuflyma®, TNF-α, Apremilast, Otezla®; Biosimilar: Apremilast Accord®, PDE-4, Bimekizumab, Bimzelx®, IL-17A/IL-17F/IL-17AF, Brodalumab, Kyntheum®, IL-17RA, Certolizumab Pegol, Cimzia®, Deucravacitinib, Sotyktu®, TYK2, Etanercept, Enbrel®; Biosimilars: Benepali®, Erelzi®, Fubelv®, Nepexto®, Guselkumab, Tremfya®, IL-23, Icotrokinra, Infliximab, Remicade®; Biosimilars: Flixabi®, Remsima®, Zessly®, Ixekizumab, Taltz®, IL-17A, Risankizumab, Skyrizi®, Secukinumab, Cosentyx®, Tildrakizumab, Ilumetri®, Ustekinumab, Stelara®; Biosimilars: Fymskina®, Imuldosa®, Otulfi®, Pyzchiva®, Steqeyma®, Usgena®, Usrenty®, Usymro®, Uzpruvo®, Wezenla®, Yesintek®, IL-12/IL-23
Prurigo nodularis
Dupilumab, Dupixent®, IL-4/IL-13, Nemolizumab, Nemluvio®, IL-31RA
Psoriasis-Arthritis
Abatacept, Orencia®, CTLA-4, Adalimumab, Humira®; Biosimilars: Amgevita®, Amsparity®, Hefiya®, Hukyndra®, Hulio®, Hyrimoz®, Idacio®, Imraldi®, Libmyris®, Yuflyma®, TNF-α, Apremilast, Otezla®; Biosimilar: Apremilast Accord®, PDE-4, Bimekizumab, Bimzelx®, IL-17A/IL-17F/IL-17AF, Certolizumab Pegol, Cimzia®, Deucravacitinib, Sotyktu®, TYK2, Etanercept, Enbrel®; Biosimilars: Benepali®, Erelzi®, Fubelv®, Nepexto®, Golimumab, Simponi®; Biosimilars: Gobivaz®, Gotenfia®, Guselkumab, Tremfya®, IL-23, Infliximab, Remicade®; Biosimilars: Flixabi®, Remsima®, Zessly®, Ixekizumab, Taltz®, IL-17A, Risankizumab, Skyrizi®, Secukinumab, Cosentyx®, Tofacitinib, Xeljanz®, JAK1/3, Upadacitinib, Rinvoq®, JAK1, Ustekinumab, Stelara®; Biosimilars: Fymskina®, Imuldosa®, Otulfi®, Pyzchiva®, Steqeyma®, Usgena®, Usrenty®, Usymro®, Uzpruvo®, Wezenla®, Yesintek®, IL-12/IL-23
Vitiligo
Ruxolitinib, Opzelura®, JAK1/2, Upadacitinib, Rinvoq®, JAK1
In Kooperation mit